BTC Capital Management Inc. Has $909,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

BTC Capital Management Inc. decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 6.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,614 shares of the company’s stock after selling 753 shares during the quarter. BTC Capital Management Inc.’s holdings in Novo Nordisk A/S were worth $909,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the company. International Assets Investment Management LLC grew its position in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the period. Mediolanum International Funds Ltd purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $98,765,000. Wellington Management Group LLP bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $42,017,000. World Investment Advisors LLC boosted its holdings in Novo Nordisk A/S by 2,655.9% in the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock worth $33,388,000 after buying an additional 270,234 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Novo Nordisk A/S by 71.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 475,490 shares of the company’s stock valued at $57,413,000 after buying an additional 198,891 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVO has been the topic of several recent analyst reports. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets cut their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Trading Up 1.5 %

Novo Nordisk A/S stock opened at $85.33 on Friday. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The company has a market cap of $382.91 billion, a P/E ratio of 27.61, a P/E/G ratio of 0.92 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business has a 50-day simple moving average of $93.97 and a two-hundred day simple moving average of $113.62.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.